Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants
BLOOD CELL THERAPY / The official journal of APBMT · 2025 · 8 (4)
DOI: 10.31547/bct-2025-011 ↗Kurz gefasst
Fachartikel in der Zeitschrift BLOOD CELL THERAPY / The official journal of APBMT, 2025. Verfasst von Anant Gokarn und 15 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplant Unit, Department of Medical Oncology, ACTREC, Tata Memorial Centre, Navi-Mumbai, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Viral reactivations frequently complicate unrelated donor (UD) and haploidentical (HI) stem cell transplants (SCTs). We analyzed incidence, risk factors, and outcomes of viral reactivations in alternative donor transplants at our center.
Methods
This retrospective study included all cases of UD or HI transplants performed between January 1, 2009 and February 29, 2020. We identified 196 viral reactivations in 87 patients in this cohort.
Results
The incidence of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) reactivation was 80.5, 36.7, and 26%, respectively. CMV colitis was observed in six patients (8.5%). Acute graft-versus-host disease (GVHD) was a significant risk factor for CMV reactivation. Four patients (5%) developed ADV disease requiring treatment with cidofovir. Anti-thymocyte globulin use and acute GVHD were significant risk factors for ADV reactivation. Mild hemorrhagic cystitis due to BK virus was observed in 32% patients. However, significant cystitis requiring intervention was seen in only four patients. Two patients developed EBV-related lymphoproliferative disorder and one patient experienced human herpes virus 6-related graft failure. Viral reactivations had no impact on overall survival.
Conclusions
The incidence of CMV reactivation in alternative donor HSCTs is high (80%) in the Indian population. Acute GVHD is a significant risk factor for CMV, ADV, or EBV reactivation. The rates of ADV, BK virus, and EBV reactivation requiring intervention are low. Better prophylactic strategies are required to prevent CMV reactivation in alternative donor transplants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bone Marrow Transplant Unit, Department of Medical Oncology, ACTREC, Tata Memorial Centre, Navi-Mumbai, India.
- Homi Bhabha National Institute, Mumbai, India.
- Department of Microbiology, Tata Memorial Centre, Mumbai, India.
- Department of Biostatistics, Tata Memorial Centre, Mumbai, India.
- Huwel Lifesciences Pvt. Ltd., Hyderabad, India.
Zitieren
APA
Gokarn, A., Murugaiyan, V., Punatar, S., Mirgh, S., Chichra, A., Jindal, N., Bonda, A., Nayak, L., Bagal, B., Bain, G., Bhat, V., Biswas, S., Kannan, S., Tripathi, R., Kumar, S., & Khattry, N. (2025). Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants. BLOOD CELL THERAPY / The official journal of APBMT, 8(4). https://doi.org/10.31547/bct-2025-011
Vancouver
Gokarn A, Murugaiyan V, Punatar S, Mirgh S, Chichra A, Jindal N, et al. Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants. BLOOD CELL THERAPY / The official journal of APBMT. 2025;8(4). doi:10.31547/bct-2025-011
BibTeX
@article{Gokarn2025,
author = {Gokarn, Anant and Murugaiyan, Vinodhini and Punatar, Sachin and Mirgh, Sumeet and Chichra, Akanksha and Jindal, Nishant and Bonda, Avinash and Nayak, Lingaraj and Bagal, Bhausaheb and Bain, Gaurav and Bhat, Vivek and Biswas, Sanjay and Kannan, Sadhana and Tripathi, Rachana and Kumar, Shesheer and Khattry, Navin},
title = {Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants},
journal = {BLOOD CELL THERAPY / The official journal of APBMT},
year = {2025},
volume = {8},
number = {4},
doi = {10.31547/bct-2025-011}
}
EUVIMED